Dare Bioscience Inc (DARE)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.62-5.73%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · DARE
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
[/TABLE] [TABLE] ● | Continued preparations for DARE to PLAY Sildenafil Cream prescription dispensing, with nationwide prescription intake and early preorder activity underway through the DARE Health…
Stated in 2 of 2 supplied quarters. Management reported: “Eastern Time – Access the webcast here SAN DIEGO, August 13, 2026 (GLOBE NEWSWIRE), Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today reported financial results for the quarter ended June 30, 2026, and provided a corporate update highlighting key milestones in its commercial evolution, including the launch of Flora Sync LF5, its first directly commercialized product.” “Revenue Total revenue for the three months ended June 30, 2026 was $0.2 million compared to $(0.02) million for the same period of the prior year.” Revenue was $0.188 million in 2026-Q2.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“[/TABLE] [TABLE] ● | Continued preparations for DARE to PLAY Sildenafil Cream prescription dispensing, with nationwide prescription intake and early preorder activity underway through the DARE Health…”
“Bravado Pharmaceuticals, the 503B-registered outsourcing facility for DARE to PLAY, is targeting the commencement of national dispensing this summer, in the third quarter of 2026, as Bravado advances…”
Eastern Time – Access the webcast here SAN DIEGO, August 13, 2026 (GLOBE NEWSWIRE), Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in…
Stated in 2 of 2 supplied quarters. Management reported: “Eastern Time – Access the webcast here SAN DIEGO, August 13, 2026 (GLOBE NEWSWIRE), Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today reported financial results for the quarter ended June 30, 2026, and provided a corporate update highlighting key milestones in its commercial evolution, including the launch of Flora Sync LF5, its first directly commercialized product.” “Revenue Total revenue for the three months ended June 30, 2026 was $0.2 million compared to $(0.02) million for the same period of the prior year.” Revenue was $0.188 million in 2026-Q2.
“Eastern Time – Access the webcast here SAN DIEGO, August 13, 2026 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in…”
“The company’s first DARE to RESTORE product, Flora Sync LF5™ – a vaginal probiotic suppository developed by Probiotical, one of the world’s leading probiotic research companies – is expected to launc…”
[/TABLE] [TABLE] ● | DARE-HPV - Investigational Therapeutic with Potential to be the First for High-Risk HPV Infection [/TABLE] [TABLE] ○ | With funding from an ARPA-H award, initiated a Phase 2 stud…
Stated in 2 of 2 supplied quarters. Management reported: “Eastern Time – Access the webcast here SAN DIEGO, August 13, 2026 (GLOBE NEWSWIRE), Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today reported financial results for the quarter ended June 30, 2026, and provided a corporate update highlighting key milestones in its commercial evolution, including the launch of Flora Sync LF5, its first directly commercialized product.” “Revenue Total revenue for the three months ended June 30, 2026 was $0.2 million compared to $(0.02) million for the same period of the prior year.” Revenue was $0.188 million in 2026-Q2.
“[/TABLE] [TABLE] ● | DARE-HPV - Investigational Therapeutic with Potential to be the First for High-Risk HPV Infection [/TABLE] [TABLE] ○ | With funding from an ARPA-H award, initiated a Phase 2 stud…”
“The DSMB recommended the study continue without modification, consistent with its findings from the first interim analysis in July 2025.”
Eastern Time – Access the webcast here SAN DIEGO, August 13, 2026 (GLOBE NEWSWIRE), Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in…
Stated in 2 of 2 supplied quarters. Management reported: “Eastern Time – Access the webcast here SAN DIEGO, August 13, 2026 (GLOBE NEWSWIRE), Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today reported financial results for the quarter ended June 30, 2026, and provided a corporate update highlighting key milestones in its commercial evolution, including the launch of Flora Sync LF5, its first directly commercialized product.” “Revenue Total revenue for the three months ended June 30, 2026 was $0.2 million compared to $(0.02) million for the same period of the prior year.” Revenue was $0.188 million in 2026-Q2.
“Eastern Time – Access the webcast here SAN DIEGO, August 13, 2026 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in…”
“We believe Share Exhibit 99.1 product revenue from these commercially launched products, alongside capital raised through equity financing and non-dilutive grant funding, will give Daré a complementa…”
Begin recording product revenue from DARE to PLAY starting in Q2/Q3 2026 as dispensing and sales commence.
Over the trailing year it converted 1.35x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
17 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-05.